Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sacituzumab govitecan + toripalimab
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Sacituzumab govitecan + toripalimab is a combination therapy under investigation for advanced cancers, particularly as a first-line treatment for advanced or metastatic triple-negative breast cancer (TNBC). Sacituzumab govitecan is an antibody-drug conjugate (ADC) that targets TROP-2 on tumor cells; it delivers the topoisomerase I inhibitor SN-38 via a humanized anti-TROP-2 antibody, causing DNA damage and apoptosis in target cells. Toripalimab is a humanized IgG4 monoclonal antibody that acts as an immune checkpoint inhibitor by blocking the programmed cell death protein 1 (PD-1) receptor, reactivating T cells to enhance anti-tumor immune responses. Together, this combination unites targeted cytotoxic activity with immune checkpoint blockade to improve anti-cancer efficacy, with ongoing studies in the first-line setting for TNBC and other malignancies[1][2][4][5][7].
- Other names
- sacituzumab govitecan and toripalimab
02
Targets
TACSTD2 (Tumor-associated calcium signal transducer 2)TOP1 (DNA Topoisomerase I)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on sacituzumab govitecan + toripalimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sacituzumab govitecan + toripalimab.